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Objective: To compare the clinical impact of a prophylactic treatment with sublingual
immunostimulation in the prevention of recurrent urinary tract infections (rUTIs) with the
use of antibiotics.
Material and Methods: Retrospective cohort study evaluating the medical records
of 669 women with rUTIs; 339 had a 6-month prophylaxis with antibiotics and 360 a
3-month prophylaxis with a sublingual bacterial preparation (MV 140-Uromune®). The
time frame after the prophylaxis-period until the appearance of a new infection (assessed
by uroculture) was scored and followed during 1 year. The absolute risk reduction (ARR)
and number needed to treat (NNT) were also calculated.
Results: All patients treated with antibiotics experienced a new UTI during the
scoring period of 12 months, being 19 days the median number of days free of UTIs
(range 5–300). In the group treated with the bacterial preparation, 35 (9.7%) patients
experienced an UTI in the same period. Kaplan-Meier curves comparing the accumulated
survival (disease-free time) between both groups were significant different (P < 0.0001).
The absolute risk reduction (ARR) was 90.28% (87.18–93.38) and the number needed
to treat (NNT) 1.1 (1.1–1.1).
Conclusions: These results suggest that the treatment with this bacterial preparation
significantly reduces the incidence of rUTIs, arising as an effective strategy to reduce
the frequency of rUTIs. It reduces antibiotic consumption, matching the current
recommendations due to the raise of antimicrobial resistance. Randomized, double-blind
and placebo-controlled, clinical trials are needed to establish, more accurately, the clinical
impact of this bacterial preparation in patients with rUTIs.
Keywords: recurrent urinary infections, bacterial vaccine, Uromune (MV 140)
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Introduction
Symptomatic urinary tract infections (UTIs) are defined when
there are clinical symptoms indicative of infection and the
presence of pathogens can be verified (Johansen et al., 2011).
These are the most frequent bacterial infections in human
(Foxman, 2002; Nicolle, 2005) and the first infection recorded
in hospital the setting (Salvatore et al., 2011), in which 2% of
the hospitalized patients acquire UTIs. In the 1980s decade,
nosocomial infections accounted for more than 500,000 cases per
year (Mayer, 1980; Turck and Stamm, 1981), being the bladder
the most common site of infection (cystitis). At least 25% of the
patients having an UTI will have a recurrence within 6 months,
with 48% of them happening during the 1 year (Salvatore et al.,
2011). Twenty two percent will have recurrent urinary tract
infections (rUTIs). Because the vast majority of these infections
are of their bacterial origin (Foxman, 2002; Nicolle, 2005),
antibiotics are the main etiological treatment.
rUTIs have an important clinical impact on the health and
quality of life of patients, together with a great economic impact.
The annual cost in the United States is estimated to be more than
2.5 billion dollars (Rahn, 2008), including millions of courses
of therapy with antibiotics (Foxman et al., 2000). Each episode
of acute UTI in pre-menopausal women is associated with 6.1
days of disability, 2.4 days of school or work absenteeism and,
in average, 0.4 days in bed (Foxman, 2002).
Women are 8–30 times more likely to have UTIs than men
(Cox et al., 1968; Naber et al., 2009), with a peak between
16 and 35 years of age. Usually, over one third of women
report at least one UTI in their lifetime (Salvatore et al., 2011),
becoming a common condition diagnosed and treated by general
practitioners, urologists, gynecologists and other health care
providers (Foxman, 2002). From the epidemiological point of
view, 2 to 3% of women between 15 and 24 years of age have
bacteriuria, raising to 20% in women between 65 and 80 years
and to 25–50% in women older than 80 years (Mulholland, 1986).
The European Commission estimates that the population group
over 65 years of age will increase 1.5-times in Europe between
2000 and 2030 (European_Commission, 2010), and the United
States Census Bureau estimates that number of women older than
65 will double in the United States (U.S._Census_Bureau, 2008).
Therefore, this situation clearly anticipates that the number of
UTIs will significantly increase in the upcoming years.
The current advised therapy for the prevention of
rUTIs is the continuous prophylaxis with antibiotics,
being the most recommended option the treatment with
Sulfamethoxazole/Trimethoprim (SMX/TMP) or Nitrofurantoin
for a period of 6 months (Nicolle and Ronald, 1987; Hooton,
2001; Grabe et al., 2013). However, long term antibiotic
consumption is not innocuous for the patient, and problems
derived from the deleterious effects on the gut microbiota and/or
the potential adverse events associated with its use is always
a concern. In addition, the continuous use of antibiotics is
associated with the widely increase of antimicrobial resistance
to antibiotics creating a dramatic situation that demands a
global challenge (Howard et al., 2014) involving governments
(Walsh, 2014), health (European_Medicines_Agency, 2014;
Food_and_Drug_Administration U. S., 2014; World-
Health_Organization, 2014), and economic (World-Economic-
Forum, 2014) organizations, among others, leading to the
conclusion that the use of antibiotics as suppressive therapy or
long-term prophylaxis may no longer be advisable (Pallett and
Hand, 2010).
We previously found in an observational retrospective study
when treating rUTIs, that the improvement of the patients
treated with this sublingual preparation (for a period of
3 months) compared with the prophylactic treatment with
antibiotics (for a period of 6 months) was 75% in the first
3 months and 86 and 77% at 9 and 15 months (Lorenzo-
Gómez et al., 2013). To investigate the preventative value of
both treatments, this study aims to address specifically the
disease-free time after each treatment course evaluating the time
between the onset of a new infection after the prophylactic course
of a commercially available mucosal immunostimulant (MV-
140 Uromune R©) compared with the currently recommended
prophylaxis with SMX/TMP or nitrofurantoin.
Methods
Study Design
It was a cohort to estimate the absolute risks in subjects with
rUTIs, in order to determine whether the prophylactic treatment
with Uromune is associated with a lower risk of new UTI.
Recurrent UTI was defined as 3 or more culture-documented
infections in a year, or 2 or more in 6 months (Rahn, 2008).
The Figure 1 shows the flow-chart and distribution of the
subjects.
The study protocol was reviewed and approved by the Ethical
Review Board of the University of Salamanca (Spain).
Study Population
Sample size was calculated using the software Epidat 3.1 (Xunta
de Galicia and PanAmerican Health Organization). The sample
size estimation for survival analysis is based on the publication
by Ahnn (Ahnn and Anderson, 1995). For 2 groups, with
a confidence level of 95%, power of 80% and expecting a
probability of survival of 40% in the groups treated with
Uromune R© and 30% in the group treated with prophylaxis with
antibiotics, the estimated number of patients per group is a
minimum of 324.
First, we screened 12564 medical records belonging to 5
primary care centers and the Urology Unit of the University
Hospital of the health area of Salamanca (Spain), searching
for those in which was clearly stated that the patients were
diagnosed and treated of rUTI, finding that 425 were treated
with Uromune and 489 with SMX/TMP or Nitrofurantoin. All
definitions of “rUTI” found in the files studied were accepted
except 65 in the group of patients treated with Uromune and
150 in the group of antibiotics. These were discarded due to
the lack of relevant data (no information regarding urocultures,
number of infections before the initiation of treatment, etc.).
It was checked that the treating doctors followed local and
international guidelines (Grabe et al., 2010, 2013) regarding
diagnosis (urinary irritative symptomatology -dysuria, frequency
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FIGURE 1 | Flow chart of the study.
and urgency- with the absence of vaginal discharge or irritation
and the corresponding positive uroculture of >103 cfu/mL
of uropathogens in a mid-stream sample of urine in acute
uncomplicated cystitis in women).
Finally, we reviewed the data from the medical records
that had enough information regarding the description of the
infection, the result of the uroculture, data of antibiogram
and antibiotic resistance, etc. The medical records were of 360
women who were treated with Uromune R© for a period of
3 months (group A) and the data of 339 who were treated
with SMX/TMP (n = 271), or Nitrofurantoin (n = 68) for
a period of 6 months (Group B) (Figure 1). Nitrofurantoin
was chosen when the infective bacteria were resistant to
SMX/TMP (57 Escherichia coli, 10 Proteus mirabilis and 1
Klebsiella pneumoniae). Epidemiological data related to age,
years of evolution of rUTIs, medical and surgical background,
sexual habits, obstetric/gynecological records, specific treatment
and evolution were recorded and analyzed (Table 2). Patients
with chronic kidney insufficiency and/or under treatment
with immunosuppressors were not included. There were no
differences between groups, regarding age, ethnicity, dietetic
habits, coital activity, hormonal status, or usual treatment. The
bacteria-positive urocultures responsible of the UTIs in the 3
months previous to the prophylactic treatment are shown in
Table 3.
Treatments
Patients in group A received Uromune R© for a period of
3 months. This is a sublingual bacterial immunostimulant
produced under GMPs (as specific named patient formulation)
by Inmunotek (Madrid, Spain) and marketed in Spain by
Q-Pharma (Alicante, Spain). The preparation consisted of 2 vials
containing a suspension of 109 inactivated whole bacteria/mL,
containing a mixture of equal amounts of selected strains
of Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris,
and Enterococcus faecalis. These microorganisms are those
producing the majority of rUTIs in Europe (Andreu and
Planells, 2008). The preparation was delivered by means of a
pump-spray to the oral/sublingual mucosa and the dose was
2 puffs of 100µL each (108 bacteria/puff) daily, avoiding the
concomitant intake of food or beverage. The delivered dose was
maintained under the tongue for a period of 1–2min and then
swallowed.
Patients in group B received a daily dose of SMX/TMP
(200/40mg/day) or nitrofurantoin (100mg/day) orally as a
prophylactic treatment for a period of 6 months (Nicolle and
Ronald, 1987; Hooton, 2001; Grabe et al., 2013).
Evaluation
The following data was collected from the medical records: (1)
the number of years that patients had rUTIs before initiating
prophylaxis; (2) number of UTIs with the corresponding
urocultures (UC) in the previous 3 months and causative bacteria
with the corresponding antibiogram; (3) the elapsed time from
the last day of the prophylactic treatment since the first episode
of UTI confirmed by UC and the identification of the causative
bacteria, establishing as limit of review 12months after the end of
the prophylactic treatment. The time period before the onset of a
new UTI after the prophylactic treatment was the main outcome
of this study.
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Statistics
The Excel spreadsheet (Microsoft, Inc. USA) with the statistical
add-in XLStat (Addinsoft, Paris, France) was used. The results
were analyzed for normality (Shapiro-Wilk), showing that all
the outcomes did not follow a normal distribution. Descriptive
statistics were expressed as the median with the first and third
interquartile range (IQR).
Mann-Whitney test and Fisher’s exact test were used to
compare between groups the epidemiological data (Table 1)
and the bacteria responsible (Table 2). The proportions of
patients in each treatment group remaining infection-free over
time were compared using Kaplan-Meier’s estimator. Absolute
risk reduction (ARR) and number needed to treat (NNT),
with the corresponding 95% confidence intervals, were also
calculated.
TABLE 1 | Chart of the study.
Free of new UTI after the
prophylactic treatment
Yes No
Patients treated 3 months with Uromune 325 35
Patients treated 6 monts with antibiotics* 0 339
*SMX/TMP or Nitrofurantoin.
TABLE 2 | Demographic data of the patients.
A (n = 360) B = 339 P
Age# 60 (44–70) 59 (49–69) 0.3384
Age range 17–85 19–91
Years of evolution before prohylactic
treatment#
6 (4–8) 7 (4–9) 0.7523
Clinical variables*
Regular sexual activity 276 270 0.3609
Menopause 170 136 0.7572
Miltiparous 163 139 0.2849
Nulliparous 91 87 0.9309
Diabetes mellitus 66 51 0.2655
Drug allergy 66 68 0.5658
Arterial hypertension 118 92 0.1168
Eutocic childbirth 197 191 0.7035
Dystocic childbirth 75 59 0.2903
Breathing disorders 66 47 0.1232
Stomach disorders 102 83 0.2653
Surgical correction of urinary
incontinence
70 81 0.1681
Surgical correction of cystocele 34 38 0.4576
Hysterectomy 127 106 0.2967
Double oophorectomy 111 89 0.2091
Smoking habit 113 91 0.2118
Obesity 102 75 0.0676
Antidepresant/anxiolytic drugs 138 123 0.5848
*Fisher’s exact test; #Mann-Whitney’s test.
Results
Both groups of patients were similar in the number of UTIs,
UC+ (Table 2) and antibiotic resistances (Table 3) before the
commencement of the prophylactic treatments.
Patients of groups A had a median of 6 (Cox et al., 1968;
Mayer, 1980; Turck and Stamm, 1981; Foxman et al., 2000; Rahn,
2008; Salvatore et al., 2011) UTIs in the previous 12 months
before to initiate the prophylactic treatment. The figures in
group B were 6 (Salvatore et al., 2011; Mayer, 1980; Turck and
Stamm, 1981; Rahn, 2008; Foxman et al., 2000; Cox et al., 1968)
(P = 0.7521).
Safety
No report of side effect, either local, in the oral mucosa, or
systemic, was recorded after the use of MV-140 Uromune R©.
Urinary Tract Infections
During the period of time of the prophylactic treatment, 290
patients (81%) of group A were free of infection in contrast with
9 (3%) of group B (P < 0.0001). After this treatment, in all group
A, 35 (9.7%) patients experienced a new UTI episode, being the
median of 180 (105–325) days (range 60–360) after ending the
treatment with the bacterial preparation. In contrast, all patients
in group B experienced the first new UTI episode in the 12
months review. The median time to experience a new UTI was
TABLE 3 | UTIs with the corresponding positive urocultures and bacteria
responsible in the 3 months previous to the initiation of the prophyactic
treatment.
A (n = 360) % B (n = 339) % P
Positive urocultures* 515 100 503 100
Citrobacter farmeri 0 0 0 0 > 0.9999
Citrobacter freundii 4 1 0 0 0.1244
Corynebacterium sp 0 0 4 1 0.0592
Citrobacter koseri 4 1 0 0 0.1244
Enterobacter aerogenes 4 1 6 1 0.5424
Enterobacter cloacae 11 2 0 0 0.0009
Enterococcus avium 0 0 3 1 0.1203
Enterococcus faecium 0 0 4 1 0.0592
Enterococcus faecalis 42 8 18 4 0.0028
Escherichia coli 310 60 333 66 0.0513
Klebsiella oxytoca 21 4 12 2 0.1569
Klebsiella pneumoniae 35 7 54 11 0.0544
Morganella morganii 4 1 4 1 > 0.9999
Proteus mirabilis 32 6 39 8 0.4629
Proteus vulgaris 0 0 0 0 > 0.9999
Pseudomonas aeruginosa 4 1 0 0 0.1244
Routella planticola 8 2 0 0 0.0076
Salmonella 4 1 0 0 0.1244
Staphylococcus aureus 0 0 0 0 > 0.9999
Staphylococcus saprophyticus 16 3 5 1 0.0253
Streptococcus agalactiae 16 3 21 4 0.4047
*Comparison: Fisher’s extact test.
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19 (12–30) days, range 5–300 days (Tables 1, 4). There was no
difference between the patients treated with SMX/TMP and those
treated with nitrofurantoin (P = 0.33). The differences between
both antibiotic subgroups in the accumulated survival (Kaplan-
Meier, Figure 2) were not significant (log rank P value = 0.75).
The differences between groups A and B in the accumulated
survival (Kaplan-Meier) were highly significant (log rank P
value < 0.0001). The ARR was 90.28% (87.18–93.38) and NNT
1.1 (1.1–1.1).
Regarding antimicrobial resistances following prophylaxis,
the total number of resistant bacteria decreased in group A
because the decrease in new UTIs. However, the statistical
analysis showed that there were no differences between groups in
the increase of antibiotic-resistant bacteria after the prophylactic
treatment (Table 5).
Some patients in group A had previous infections with
bacteria that were not included in the MV-140 formulation
(Table 3). After the 3 months of treatment with this preparation,
the patients remained UTI-free 12 months later (Table 4), and
therefore, also free of infections due to these bacteria.
Discussion
In this retrospective study we have compared the administration
of a sublingual bacterial preparation (MV-140 Uromune R©) with
the currently recommended use of antibiotics for a period of 6
months (Grabe et al., 2013).
In this study, patients treated for a period of 3 months with
MV-140 Uromune R© had a significantly longer UTI-free time
interval than patients treated during 6 months with SMX/TMP
or nitrofurantoin. The review of the medical records indicated
that 90.3% (325 patients) of the patients treated with MV-140
Uromune R© remained free of new UTI, in contrast with 0% of
patients treated with the conventional antibiotic prophylaxis.
Thus, patients treated with MV-140 Uromune R© experienced
a much better clinical improvement than those treated with
antibiotics. The ARR of 93.38 and the NNT of 1.1, as measures
of effectiveness of treatment specificity, means that the favorable
outcome occurs practically in every patient who receivedMV-140
Uromune R© and in no patient receiving antibiotic.
To the best of our knowledge, this is the first study to report a
survival analysis of 12 months after the use of mucosal sublingual
immunostimulation showing such a degree of effectiveness.
Hopkins (Hopkins et al., 2007) reported a survival analysis for
a period of 160 days using mucosal vaginal immunostimulation
vs. placebo. In this study each patient received 3 initial
vaginal suppositories weekly followed by 3 additional monthly
suppositories. No significant differences were observed, except
in a group of patients who received an additional booster. The
patients free of new UTI in the 160 days of follow-up were 16.7%
TABLE 4 | UTIs with the corresponding positive urocultures and bacteria responsible after the period of the the prophyactic treatment.
A (n = 360) % B (n = 339) % P
Patients with UTI* 35 339 < 0.0001
Median of days of evolution until first UTI# 180 (105–235) 19 (12–30) < 0.0001
Positive urocultures* 35 100 339 100 < 0.0001
Citrobacter farmeri 0 0 4 1 > 0.9999
Citrobacter freundii 0 0 4 1 > 0.9999
Corynebacterium sp 0 0 0 0 > 0.9999
Citrobacter koseri 0 0 0 0 > 0.9999
Enterobacter aerogenes 0 0 5 1 > 0.9999
Enterobacter cloacae 0 0 0 0 > 0.9999
Enterococcus avium 0 0 0 0 > 0.9999
Enterococcus faecium 0 0 4 1 > 0.9999
Enterococcus faecalis 4 11 15 4 0.0901
Escherichia coli 25 71 220 65 0.5756
Klebsiella oxytoca 3 9 5 1 0.0304
Klebsiella pneumoniae 0 0 39 12 0.0365
Morganella morganii 0 0 0 0 > 0.9999
Proteus mirabilis 0 0 24 7 0.1487
Proteus vulgaris 0 0 3 1 > 0.9999
Pseudomonas aeruginosa 0 0 0 0 > 0.9999
Routella planticola 0 0 0 0 > 0.9999
Salmonella 0 0 0 0 > 0.9999
Staphylococcus aureus 3 9 0 0 0.0008
Staphylococcus saprophyticus 0 0 4 1 > 0.9999
Streptococcus agalactiae 0 0 12 4 0.6134
#only patients who experienced UTI. Comparison: Mann-Whitney’s test.
*Comparison: Fisher’s extact test.
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FIGURE 2 | Evolution of percent of women remaining free of UTI.
TABLE 5 | Number of bacteria producing infections and number of
bacteria resistant to different antibiotics, before and after the prohylactic
treatment.
Group A Group B P*
Isolated Resistant Isolated Resistant
bacteria bacteria
Before prophylaxis 515 199 (39%) 503 219 (44%) 0.1262
After prophylaxis 35 11 (31%) 339 153 (45%) 0.1522
P* 0.4738 0.6714
*Fisher’s exact test.
No differences were observed intra and inter groups.
in the placebo group, 25% in the active group and 46% in the
active group with a booster. In our study, 340 (94.4%) patients
who received sublingual prophylaxis were free of a new UTI after
160 days, demonstrating a higher clinical benefit.
The results obtained in the current study reinforce those
shown in a previous publication (Lorenzo-Gómez et al.,
2013), in which the main outcome was the number of UTIs
after the initiation of the prophylactic treatment with MV-
140 Uromune R©, or antibiotics. Patients treated with MV-140
Uromune R© for a 3-month period had an improvement greater
than 75% in the number of new UTIs when compared to
patients treated with SMX/TMP for a period of 6 months.
The benefit of Uromune R© was maintained after an observation
period of 9 and 15 months (86 and 77% of improvement,
respectively).
The use of bacterial preparations to prevent rUTIs was
recommended in 2009 by the European Association of Urology
(Grabe et al., 2010) and in 2013 (Grabe et al., 2013) recommended
one preparation and the conduction of large phase III studies for
other immunotherapeutics. The comparison of an oral bacterial
lysate of 109 E. coli with nitrofurantoin, as a prophylaxis for
rUTIs in girls, was reported by Lettgen et al (Lettgen, 1996),
showing that the efficacy of the long-term administration of this
bacterial lysate was comparable to that of nitrofurantoin.
Bauer reported in 2005 (Bauer et al., 2005) a double blind,
placebo controlled study in 454 women using a similar approach
consisting in an oral administration of capsules containing
freeze-dried lysate of E. coli. Patients were treated with 1 capsule
(active or placebo) per day for 90 days, followed by 3 months
without treatment, and then the capsules were taken again only
the first 10 days in months 7, 8, and 9. These patients were
followed up during 12 months, reporting a 34% reduction of
UTIs in patients treated with the bacterial lysate when compared
to placebo. The same authors (Bauer et al., 2002) reported in 2002
ameta-analysis performed on 5 studies of this oral bacterial lysate
of 109 E. coli compared with placebo in double-blind studies in
patients with UTIs (601 women), showing a superiority of 35%
of this treatment over placebo. The drug was well tolerated and
patients’ compliance was excellent in all studies. However, none
of these studies reported the time free of new UTIs after the
prophylactic treatment.
In the present study, the prophylactic benefit of sublingual
immunostimulant was greater than the described with the
current available oral bacterial lysates (Lettgen, 1996; Bauer et al.,
2002, 2005) or vaginal whole bacteria preparations (Hopkins
et al., 2007). These differences could be explained by the form by
which the bacteria are formulated (whole inactivated bacteria vs.
lysate) (Sato et al., 2000; Underhill and Ozinsky, 2002; Blander
and Sander, 2012; Rosadini and Kagan, 2015), the inductive
mucosal site (Quiding et al., 1991; Kozlowski et al., 1997; Eriksson
et al., 1998; Holmgren and Czerkinsky, 2005; Çuburu et al., 2007)
(gut or vaginal vs. sublingual/oral mucosa) and/or the bacterial
strains used (Yu et al., 2007;Wiles et al., 2008; Croxen and Finlay,
2010; Ulett et al., 2013). Sublingual mucosa is an inductive site
for generating broad spectrum mucosal and systemic immune
responses, including the respiratory and genitourinary tracts
(Holmgren and Czerkinsky, 2005; Çuburu et al., 2007), with a
high degree of efficacy and persistence of the immune response
(Negri et al., 2010). Sublingual immunostimulation induces
systemic humoral dose-dependent immune responses (Çuburu
et al., 2007), mucosal antibody responses (Çuburu et al., 2007)
and an immune stimulating effect on CD4+ T helper cell
responses to bacteria (Alecsandru et al., 2011).
An interesting finding in the current study is that patients
of group A who had previous infections with bacteria not
included in MV-140 Uromune R©, such as Enterobacter aerogenes,
Enterobacter cloacae, Morganella morganii, Pseudomonas
aeruginosa, Routella planticola, Salmonella, Staphylococcus
saprophyticus, and Streptococcus agalactiae did not have new
infections with these bacteria, suggesting a broad immune
stimulation. This is supported by the enhancement of T cell
responses to flu antigens in patients treated with other sublingual
bacterial preparations (Alecsandru et al., 2011).
In summary, the results obtained in this study favor the use
of bacterial immunostimulants instead of antibiotics for the
prophylactic treatment of rUTIs as a reasonable strategy to avoid
the latter in a safe and effective way. This approach is in line
with the recommendations of all the social agents, promoting
new treatment alternatives against bacterial diseases of high
prevalence and those that may precipitate secondary bacterial
diseases (World_Health_Organization, 2001; Centers_for_
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Disease_Control_and_Prevention, 2011; European_Medicines_
Agency, 2011; Food_and-Drug_Administratrion, 2011).
We acknowledge that because this study is a compilation
of existing data with the only criteria of having rUTIs under
prophylaxis with Uromune or with antibiotics, it doesn’t
provide deeper and more accurate outcomes as those that
can be obtained in a prospective, explanatory controlled
trial conducted in clinically experimental conditions. Patients
included in this study are those that exist records regarding
follow-up. A possible weakness is the vague definition of
UTI in the medical records and a possible source of bias
was that we didn’t include patients that received treatment
but there was not follow-up. Nevertheless, the sample size
and the data collected from these medical records provides
clinically valuable information of the patients treated under
“real world” conditions, not only regarding the effectiveness
of Uromune, but in the low degree of clinical benefit of
SMX/TMP or Nitrofurantoin as prophylactic treatment. We do
believe, however, that further prospective double-blind, placebo-
controlled, randomized clinical trials are needed to establish
more accurately the clinical impact of this bacterial preparation
in patients with rUTIs.
The results obtained in this study show that treatment with the
bacterial preparation reduces rUTIs effectively, far beyond than
with the recommended antibiotic prophylaxis. Therefore, this
approach arises as an effective strategy to reduce the frequency of
rUTIs. Moreover, it reduces antibiotic consumption, which is in
line with the current recommendations of Governments, Health
and Regulatory Authorities due to the raise of antimicrobial
resistances.
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